NasdaqGM:RYTMBiotechs
Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ (RYTM) Narrative
Rhythm Pharmaceuticals has received marketing authorization in Japan for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, the first approved therapy in that indication, supported by positive Phase 3 TRANSCEND data showing a statistically significant placebo-adjusted reduction in body mass index.
This approval opens a new rare-disease market in Japan, where Rhythm estimates 5,000 to 8,000 people live with acquired hypothalamic obesity, potentially expanding the company’s...